403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Appili Therapeutics Inc.
(MENAFN- Baystreet) 10:05 AM EST - Appili Therapeutics Inc. : And its partner Vitalex Biosciences today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded up to US$40 million in funding to support the development of VXV-01, a vaccine aimed at protecting against invasive fungal infections. Appili Therapeutics Inc.
shares T are trading up $0.02 at $0.03.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- New Cryptocurrency Mutuum Finance (MUTM) Raises $15.8M As Phase 6 Reaches 40%
- Noveba Brings Apple Pay To Customers
- Mutuum Finance (MUTM) Approaches Next Phase With 14.3% Price Increase After Raising $16 Million
- Cregis And Kucoin Host Institutional Web3 Forum Discussing Industry Trends And Opportunities
- Primexbt Expands Crypto Futures With 101 New Coins, Delivering Best-In-Class Trading Conditions
- BTCC Exchange Announces Triple Global Workforce Expansion At TOKEN2049 Singapore To Power Web3 Evolution
More Story
Comments
No comment